Sign In
Buy ACHV
$4.92
-0.110 (-2.19%)
At Close: Jun 03, 2026
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2021 Results - Earnings Call Transcript
03:57am, Friday, 13'th Aug 2021
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2021 Results - Earnings Call Transcript
Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update
04:05pm, Wednesday, 11'th Aug 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercializat
Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen
05:30am, Wednesday, 11'th Aug 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercializat
Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021
05:30am, Tuesday, 03'rd Aug 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 3, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercializati
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / July 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercializatio
Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline
05:30am, Tuesday, 29'th Jun 2021
ORCA-2 Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE /
Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addiction
05:30am, Thursday, 03'rd Jun 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / June 3, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization
Achieve Life Sciences to Present at LD Micro Invitational XI Virtual Conference
05:30am, Wednesday, 02'nd Jun 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / June 2, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 27, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization
Achieve Life Sciences Stock Plunges After Raising $20M Via Equity at 19% Discount
11:33am, Tuesday, 25'th May 2021
Achieve Life Sciences Inc (NASDAQ: ACHV) has priced its underwritten public offering of 2.9 million at $7 per share, representing a discount of 19% from the last close price of $8.61. Underwriters
Achieve Life Sciences Announces Proposed Underwritten Public Offering
04:05pm, Monday, 24'th May 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 24, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2021 Results - Earnings Call Transcript
05:26pm, Thursday, 13'th May 2021
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2021 Results - Earnings Call Transcript
Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update
04:05pm, Thursday, 13'th May 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization
Achieve Life Sciences to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
05:30am, Tuesday, 04'th May 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 4, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization
Achieve Announces Publication of the ORCA-1 Phase 2b Clinical Trial of Cytisinicline in Adult Smokers in Nicotine and Tobacco Research
05:30am, Wednesday, 14'th Apr 2021
Cytisinicline Up to Five Times More Likely to Result in Smoking Abstinence Compared to Placebo Phase 3 ORCA-2 Trial Currently Enrolling at 16 sites in United States SEATTLE, WA and VANCOUVER, BC / ACC
